(NASDAQ: CLDX) Celldex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 26.44%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.98%.
Celldex Therapeutics's earnings in 2025 is -$178,851,000.On average, 17 Wall Street analysts forecast CLDX's earnings for 2025 to be -$235,951,854, with the lowest CLDX earnings forecast at -$253,108,126, and the highest CLDX earnings forecast at -$214,021,836. On average, 15 Wall Street analysts forecast CLDX's earnings for 2026 to be -$281,777,159, with the lowest CLDX earnings forecast at -$311,667,846, and the highest CLDX earnings forecast at -$244,695,975.
In 2027, CLDX is forecast to generate -$279,778,692 in earnings, with the lowest earnings forecast at -$355,912,968 and the highest earnings forecast at -$196,593,348.